HCPCS code J1750: Iron dextran injection billing guide

Key Takeaways

HCPCS code J1750 describes Injection, iron dextran (INFeD), 50 mg per billing unit — billed per 50 mg increment administered

Medicare lists J1750 with ‘special coverage instructions apply’ — providers must check the applicable Local Coverage Determination (LCD) before billing

J1750 requires a JW or JZ modifier on CMS claims to document drug wastage or confirm no wastage occurred

Practice management software like Pabau tracks J-code drug units, modifiers, and payer rules in one workflow

HCPCS code J1750 describes Injection, iron dextran, 50 mg — billed per 50 mg increment of iron dextran administered. The brand name most consistently mapped to this code is INFeD, manufactured by American Regent, used to treat iron deficiency anemia when oral iron therapy isn’t appropriate or has failed.

This guide covers unit calculation, Medicare and Medicaid reimbursement, JW and JZ modifier requirements, supporting ICD-10 diagnosis codes, NDC mapping, and how J1750 compares with related iron-replacement J-codes.

HCPCS code J1750: Definition and clinical description

A provider who administers 500 mg of iron dextran but bills 10 units without proper modifier documentation can trigger a payer audit before reimbursement even processes — the kind of error clean claims management software is built to catch.

HCPCS code J1750 codes for exactly 50 mg of iron dextran per unit. Every 50 mg increment must be counted carefully before the claim goes out.

Code properties at a glance

Billing units and dose calculation for HCPCS code J1750

J1750 is billed per 50 mg increment. That means the units billed must equal the total milligrams administered divided by 50. A 500 mg dose = 10 units. A 100 mg test dose = 2 units. Always round to the nearest whole unit based on actual dose administered.

Bill only the units actually administered to the patient. If drug is drawn from a vial but not administered (wasted), document the discarded amount using the JW modifier. Never round up to the nearest full vial unless that amount was given.

The infusion or injection itself is billed separately from the drug. IV administration is typically reported using CPT code 96365, in addition to J1750 for the iron dextran itself.

Medicare reimbursement and fee schedule for HCPCS code J1750

Medicare does not publish a fixed fee schedule amount for J1750. Reimbursement is calculated using the Average Sales Price (ASP) methodology, updated quarterly by CMS. The standard Medicare Part B formula is ASP plus 6% for separately billed drugs administered in an outpatient or office setting.

Because CMS updates ASP quarterly, billing staff should pull the current ASP payment limit from the CMS HCPCS code system before finalizing J1750 claims. Any static figure published on third-party websites will be out of date within 90 days.

Medicare coverage: What “special coverage instructions apply” means

“Special coverage instructions apply” is a CMS designation, not a coverage determination. It means Medicare does not universally cover J1750 for all diagnoses. Coverage depends on whether the claim is supported by a valid Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor (MAC) for the provider’s region.

Clinics must identify the applicable LCD, confirm the diagnosis qualifies, and document medical necessity accordingly before billing.

Providers in states served by different MACs should check their region’s LCD database directly. Presuming coverage without an LCD review is a common audit trigger for iron infusion claims.

Place of service considerations

J1750 may be billed from a physician office (POS 11), outpatient hospital (POS 22), or outpatient infusion center (POS 19), among others. Reimbursement rates vary by setting. Hospital outpatient billing typically occurs on a UB-04 claim form under the facility’s OPPS rates, while physician office billing uses the CMS-1500 form with ASP-plus-6% reimbursement.

JW and JZ modifier requirements for J1750

CMS policy requires that most single-dose vial or multi-dose vial drug claims include either a JW or JZ modifier to indicate drug wastage status. J1750 is confirmed in the CMS JW/JZ Modifier Policy HCPCS Codes document as a code subject to this requirement.

• JW modifier (drug amount discarded): Use when drug is drawn from a vial but a portion is not administered. Bill the administered amount on one line with the drug units, then bill the discarded amount on a second line using the JW modifier. The discarded units are not separately reimbursed but must be documented.
• JZ modifier (no drug discarded/wasted): Use when the entire amount drawn from the vial was administered to the patient. Attests that no drug was wasted. Required on applicable claims when no wastage occurred.

Omitting the required modifier is a compliance risk. CMS has the authority to recoup reimbursement on claims where modifier documentation is absent. Practices billing iron dextran regularly should build modifier verification into their standard IV therapy clinic billing workflows before submission.

Manage J-code drug billing in one place

Pabau's claims management tools help infusion clinics track administered drug units, apply JW and JZ modifiers correctly, and submit cleaner claims with fewer denials.

Book a demo

ICD-10 diagnosis codes that support J1750 medical necessity

Every J1750 claim needs a supporting diagnosis code that establishes medical necessity for intravenous iron replacement. The IV therapy EMR software used by infusion clinics should map these ICD-10 codes to the J1750 service line automatically at the point of documentation.

Always use the most specific ICD-10 code available. Payers increasingly require specificity. D50.9 (unspecified) may trigger additional documentation requests from some MACs when the clinical record supports a more defined code.

Acute blood loss from a sudden GI bleed is coded differently from chronic deficiency. For that scenario, see ICD-10 code D62 instead of the D50.0 codes covered above.

Documentation requirements when billing J1750

Inadequate documentation is the leading cause of post-payment audits for iron infusion claims. Each encounter record must support medical necessity and accurately reflect the administered dose. Robust IV therapy intake documentation at the point of care makes audit defense substantially easier.

Pairing that intake record with a structured anemia chart to track ferritin, TIBC, and hemoglobin trends over time strengthens the medical necessity record further.

The clinical record for a J1750 claim should include all of the following:

• Diagnosis confirmation: Lab values supporting iron deficiency anemia (serum ferritin, TIBC, hemoglobin, transferrin saturation) documented before treatment initiation
• Medical necessity narrative: Statement that oral iron therapy was contraindicated, failed, or is clinically inappropriate
• Dose ordered: Physician or NPP order specifying total iron dextran dose in milligrams
• Dose administered: Nursing administration record showing actual mg infused, start/stop times, and patient tolerance
• Test dose documentation (if applicable): If a test dose was administered before the full infusion, document separately and bill the test dose units accordingly
• Adverse reaction monitoring note: Iron dextran carries a higher risk of serious adverse reactions, including anaphylaxis, compared to newer formulations. FDA labeling for INFeD requires a test dose before the first therapeutic dose and at least a 1-hour observation period before the therapeutic dose. Document that monitoring occurred.
• Modifier rationale: Chart note or order indicating whether drug wastage occurred to support JW or JZ modifier selection

HIPAA-compliant documentation practices protect both the patient record and the billing claim. Clinics should maintain HIPAA-compliant documentation workflows that link the clinical note to the submitted billing code in a reviewable audit trail.

NDC codes associated with HCPCS code J1750

National Drug Codes (NDCs) identify the specific drug product used in an administration. HCPCS codes identify the type of service. For J1750 claims under Medicaid and many commercial payers, the NDC must appear on the claim alongside the HCPCS code.

The NDC confirms the exact drug, manufacturer, and package size used. Managing this mapping accurately requires prescription management software that stores current NDC-to-HCPCS associations and flags outdated codes.

INFeD (iron dextran) NDCs are tied to American Regent’s product configurations. Providers should verify current NDCs directly against their distributor invoices and confirm validity in the NDC database at the time of billing. NDC codes change when manufacturers update packaging, labeling, or lot configurations. Billing with a retired NDC leads to claim rejection.

When submitting NDC on a CMS-1500 or electronic claim, use the 11-digit format (5-4-2) and include the NDC unit of measure qualifier (e.g., ML for milliliters, UN for units) and the quantity dispensed. Medi-Cal and many state Medicaid programs require NDC reporting on all outpatient drug claims, including J-codes.

Coders who bill other injectable drugs regularly may also want to review our guides to HCPCS codes J1940, J0690, and J9202 for similar unit-calculation and modifier considerations.

Medicaid billing rules for J1750

State Medicaid programs have independent billing rules for iron dextran. These rules are not identical to Medicare and vary significantly by state. The NC Medicaid billing bulletin confirms that North Carolina Medicaid requires providers to bill HCPCS Code J1750 for iron dextran injections, and that documentation of medical necessity must accompany the claim.

Medi-Cal (California Medicaid) also processes J1750 claims but applies its own fee schedule and prior authorization thresholds. Providers billing iron dextran across multiple states should not assume that one state’s coverage rules apply to another.

Always pull the specific state Medicaid billing manual or drug fee schedule for each jurisdiction where iron infusion services are rendered. The mobile IV therapy billing considerations are especially relevant here, as mobile infusion providers may cross state lines and encounter different Medicaid rules by geography.

HCPCS code J1750 compared to related iron replacement codes

Iron dextran is not the only parenteral iron option, and each formulation has its own HCPCS code. Coders working at infusion centers or clinics running an IV infusion clinic need to distinguish these codes clearly, because billing the wrong code for the administered drug is an unbundling or misrepresentation risk.

The most consequential distinction for billing purposes is between J1750 and J1756. Iron dextran (J1750) is billed per 50 mg, while iron sucrose (J1756) is billed per 1 mg.

A 200 mg dose of iron dextran equals 4 units of J1750. The same dose of iron sucrose would equal 200 units of J1756. Applying the wrong code’s unit logic to the other drug is a material billing error. Verify the drug name and NDC against the claim before submission.

Prior authorization and payer coverage rules for J1750

Prior authorization requirements for J1750 vary by payer and plan type. Medicare Part B does not universally require prior authorization for iron dextran, but coverage is conditional on LCD compliance. Commercial payers, Medicare Advantage plans, and Medicaid managed care organizations frequently require pre-authorization before iron infusion services are rendered.

Clinics should establish a payer-specific prior authorization matrix for all parenteral iron J-codes. The authorization request typically requires the treating diagnosis ICD-10 code, lab values, documentation that oral iron was trialed and failed, and the planned dose and number of infusions. Consulting resources like the AAPC Codify HCPCS code database can help staff identify payer-specific coverage policies by code.

An infusion clinic’s EMR built for IV drug billing should surface prior authorization status directly within the scheduling and claims workflow so billing staff can confirm approval before the appointment, not after the claim denies.

Conclusion

Iron dextran infusion billing is not forgiving of unit errors or missing modifier documentation. J1750 claims fail when the administered dose doesn’t match billed units, when the JW or JZ modifier is omitted, or when the supporting diagnosis lacks the specificity the payer’s LCD requires.

Pabau’s digital clinical forms and claims management tools help infusion clinics capture dose documentation, link ICD-10 codes to administered drugs, and keep modifier logic consistent across every J-code claim. To see how Pabau handles buy-and-bill drug billing end to end, book a demo.

Continue your research

Need the diagnosis side covered too? ICD-11 3A00 walks through diagnostic criteria for iron deficiency anemia in dual-coding regions.

Managing drug inventory alongside infusion billing? Inventory management software helps track vial usage and support JW modifier documentation.

Worried about adverse reactions during infusion? IV therapy complications covers the warning signs infusion staff need to catch early.

Frequently asked questions